Skip to content
Carisoprodol
Soma (carisoprodol) is a small molecule pharmaceutical. Carisoprodol was first approved as Soma on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, muscle spasticity, myositis, and pain amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Soma (generic drugs available since 1982-04-20, discontinued: Rela)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aspirin
+
Carisoprodol
Tradename
Company
Number
Date
Products
SOMA COMPOUNDMeda ABN-012365 DISCN1983-07-11
1 products
Hide discontinued
Aspirin
+
Carisoprodol
+
Codeine phosphate
Tradename
Company
Number
Date
Products
SOMA COMPOUND W/ CODEINEMeda ABN-012366 DISCN1983-07-11
1 products
Hide discontinued
Carisoprodol
Tradename
Company
Number
Date
Products
SOMAMylanN-011792 RX1982-01-01
2 products, RLD
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
carisoprodolANDA2023-05-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
muscle crampHP_0003394D009120—
muscle rigidityHP_0002063D009127—
muscle spasticityHP_0001257D009128—
myositisEFO_0000783D009220G72.49
painEFO_0003843D010146R52
spasm—D013035M62.83
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BA: Carbamic acid esters, centrally acting muscle relaxants
— M03BA02: Carisoprodol
— M03BA52: Carisoprodol, combinations excl. psycholeptics
— M03BA72: Carisoprodol, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cesarean sectionD0025851————1
Female genital diseasesD005831EFO_0009549N851————1
LeiomyomaD007889HP_0000131D251————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postpartum hemorrhageD006473O72————33
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARISOPRODOL
INNcarisoprodol
Description
Carisoprodol is a carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. It has a role as a muscle relaxant.
Classification
Small molecule
Drug classCarbamate
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Identifiers
PDB—
CAS-ID78-44-4
RxCUI2101
ChEMBL IDCHEMBL1233
ChEBI ID3419
PubChem CID2576
DrugBankDB00395
UNII ID21925K482H (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 759 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
216 adverse events reported
View more details